Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Share: Prescription Drugs (Japan)

This article was originally published in PharmAsia News

Executive Summary

Changes in the prescription drug prices imposed by the Japanese government caused prices to drop 6.7 percent in the 2006 fiscal year, but sales slipped only 0.5 percent to 7.71 trillion yen. In regards to market share of pharmaceutical companies, Takeda Pharmaceutical Co. remained in the top spot, with increased sales of its Actos diabetes medication pushing its market share up 0.2 percentage points to 8 percent. Astellas Pharma Inc. came in second at 7.2 percent, reporting strong sales of Prograf, which safeguards against organ rejection in transplant patients. Ranking third was Daiichi Sankyo Co. with 6.5 percent of the market, recording a 0.2 percentage point drop due to weaker sales of its Mevalotin cholesterol medication in response to the availability of generics. Chugai Pharmaceutical Co. fell to No. 5 in terms of market share, with Pfizer Japan Inc. taking over its spot in fourth place. (Click here for more

You may also be interested in...



Commercial Partner Sought For Nasal Spray Claimed To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

Russia Prepares $10 COVID-19 Vaccine For International Launch

Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.

Galapagos Sells CRO To Selvita For €31.2m

The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel